Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection.

Liu C. et al, (2024), Nature communications, 15

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.

Zhou D. et al, (2024), Nature communications, 15

Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.

Wei J. et al, (2024), Nature communications, 15

Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques.

Keelapang P. et al, (2023), Journal of virology, 97

The molecular reach of antibodies determines their SARS-CoV-2 neutralisation potency

Huhn A. et al, (2023)

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.

Hornsby H. et al, (2023), Nature communications, 14

Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody.

Keelapang P. et al, (2023), Microbiology spectrum

Corrigendum: Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Thursz M. et al, (2023), The Journal of general virology, 104

Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Thursz M. et al, (2023), The Journal of general virology, 104

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.

Ragonnet-Cronin M. et al, (2023), Nat Commun, 14

Accelerating drug target inhibitor discovery with a deep generative foundation model.

Chenthamarakshan V. et al, (2023), Science advances, 9

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

Wei J. et al, (2023), Nature Communications, 14

COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.

Buckell J. et al, (2023), Scientific reports, 13

Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.

Yin Z. et al, (2023), Cell Rep, 42

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].

Liu X. et al, (2023), J Infect

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), J Infect

Isolation of a pair of potent broadly neutralizing mAb binding to RBD and SD1 domains of SARS-CoV-2

Stuart D. et al, (2023)

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.

Dijokaite-Guraliuc A. et al, (2023), Cell reports, 42

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.

Moore SC. et al, (2023), Med (N Y)

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

Emmenegger M. et al, (2023), iScience, 26, 105928 - 105928

Load More

1
2
3
4
5
6

Include forthcoming?